만성신장병 시장 : 유형, 적응증, 최종사용자별 - 세계 예측(2024-2030년)

[182 Pages Report] The Chronic Kidney Disease Market size was estimated at USD 128.45 billion in 2023 and expected to reach USD 136.56 billion in 2024, at a CAGR 6.50% to reach USD 199.64 billion by 2030.

Chronic kidney disease (CKD) is a medical condition characterized by a gradual loss of kidney function over time. The kidneys are essential organs that filter out toxins, excess salts, and urea, a waste product from normal body functions. When the kidneys are damaged, they cannot perform these functions effectively, accumulating harmful substances in the body. CKD is often progressive, which means it can worsen over time and may eventually lead to kidney failure, requiring dialysis or kidney transplantation. The increasing prevalence of chronic kidney disease, especially among the aging population, is expanding the need for chronic kidney disease treatments. Improved awareness about kidney health and the development of advanced diagnostics for early detection of CKD contribute to higher diagnosis rates, driving the growth of the chronic kidney disease market. The high cost of chronic kidney disease treatments hampers the market growth. Rising healthcare services and better access to medical care in many regions of the world that allow more people to receive treatment for conditions that contribute to CKD are expected to create opportunities for market growth.

Regional Insights

In the Americas, there is a high prevalence of CKD, largely attributed to increasing rates of diabetes and hypertension, which are significant risk factors for the disease. The Americas shows significant investment in healthcare infrastructure and a strong presence of healthcare services that boost the management of chronic diseases, including CKD. Awareness programs, advanced healthcare facilities, and government-funded initiatives also help manage and treat CKD. In South America, rising efforts to improve healthcare accessibility and quality with the increasing need for the management of chronic diseases are creating a platform for market growth of chronic kidney disease treatment in the Americas. The Asia-Pacific region presents a diverse picture due to varying socioeconomic status across countries. Countries such as China, India, Japan, and Australia have well-established healthcare systems capable of managing chronic diseases effectively. The awareness about CKD is growing in this region, and governments along with private organizations, are making strides towards better screening, awareness campaigns, and improving healthcare infrastructure. Europe has a robust healthcare infrastructure and relatively high awareness about CKD, aided by strong government support and healthcare policies that ensure relatively better management of the condition. The Middle East shows variability with affluent nations including, Saudi Arabia and the UAE investing heavily in healthcare, whereas less affluent areas struggle with similar issues as seen in developing regions. Africa faces more pronounced challenges in dealing with CKD due to limited healthcare infrastructure, lower awareness, and other socio-economic challenges that complicate disease management and treatment availability.

Market Insights

• Market Dynamics

The market dynamics represent an ever-changing landscape of the Chronic Kidney Disease Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing global prevalence of chronic kidney disease with the aging population
  • Supportive government and regulatory policies aimed at improving healthcare infrastructure
  • Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments

• Market Restraints
  • High cost and gap in product standardization across regions

• Market Opportunities
  • Advancements in treatment and diagnostic technologies and product innovation
  • Expansion of telemedicine and remote monitoring technologies

• Market Challenges
  • Limited commercialization of advanced kidney disease treatments
• Market Segmentation Analysis
  • Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
  • End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services

• Market Disruption Analysis
• Porter's Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Chronic Kidney Disease Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Chronic Kidney Disease Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients

Akebia Therapeutics, Inc. announced that Vafseo (vadadustat), their new oral medication, has received FDA approval to treat anemia in adults with chronic kidney disease (CKD) who have been on dialysis for a minimum of three months. This once-daily tablet functions as a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which mimics the body's natural response to low oxygen levels, thereby enhancing the production of erythropoietin. This mechanism assists in managing anemia effectively. Vafseo has also gained approval in 37 other countries, marking a significant advancement in CKD treatment options. [Published On: 2024-03-27]

FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses

The U.S. Food and Drug Administration (FDA) has recently granted approval for the use of Jardiance (empagliflozin) 10 mg tablets to help mitigate the risk of severe outcomes associated with chronic kidney disease (CKD) in adults at risk of progression. These outcomes include a sustained decline in the estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization. [Published On: 2023-09-22]

Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members

Signify Health expanded its Diagnostic and Preventive Services by introducing an in-home kidney health evaluation for Medicare Advantage members. This assessment, conducted during an in-home health evaluation at no extra cost, aims to detect and manage kidney-related health issues early. It includes critical tests such as urinalysis (uACR) and estimating the glomerular filtration rate (eGFR). These results enable healthcare professionals and patients to collaboratively design personalized management plans, potentially comprising further tests, lifestyle adjustments, pharmaceutical interventions, and nephrologist referrals. [Published On: 2023-08-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Chronic Kidney Disease Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Diagnosis
    • Blood Tests
    • Imaging Tests
    • Kidney Biopsy
    • Urine Tests

• Treatment
  • Dialysis
  • Kidney Transplant
  • Medication
    • ACE Inhibitors
    • Angiotensin Receptor Blockers
    • Beta Blockers
    • Diuretics
    • Erythropoietin Stimulants
    • Finerenone
    • Glucagon-like Peptide-1 Receptor Agonists
    • Insulin
    • Metformin
    • Potassium Binders
    • Sodium-glucose Cotransporter-2 Inhibitors
    • Statins
• Indication
  • Chronic Interstitial Nephritis
  • Diabetic Nephropathy
  • Glomerulonephritis
  • Hypertensive Nephropathy
  • Obstructive Nephropathy
  • Polycystic Kidney Disease

• End-User
  • Ambulatory Surgery Centers
  • Diagnostic Centers & Laboratories
  • Hospitals & Clinics
  • Speciality Treatment Centers

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
    • 5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
    • 5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and gap in product standardization across regions
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
    • 5.1.3.2. Expansion of telemedicine and remote monitoring technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited commercialization of advanced kidney disease treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
  • 5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Chronic Kidney Disease Market, by Type

• 6.1. Introduction
• 6.2. Diagnosis
• 6.3. Treatment

7. Chronic Kidney Disease Market, by Indication

• 7.1. Introduction
• 7.2. Chronic Interstitial Nephritis
• 7.3. Diabetic Nephropathy
• 7.4. Glomerulonephritis
• 7.5. Hypertensive Nephropathy
• 7.6. Obstructive Nephropathy
• 7.7. Polycystic Kidney Disease

8. Chronic Kidney Disease Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgery Centers
• 8.3. Diagnostic Centers & Laboratories
• 8.4. Hospitals & Clinics
• 8.5. Speciality Treatment Centers

9. Americas Chronic Kidney Disease Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Chronic Kidney Disease Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Kidney Disease Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
  • 12.3.2. FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses
  • 12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio